Economic Evaluation of anti-epileptic Medicines for Autistic Children with Epilepsy
Journal of Autism and Developmental Disorders · 2024
DOI: 10.1007/s10803-023-05941-8 ↗At a glance
Journal article in Journal of Autism and Developmental Disorders, 2024. Written by Michela Tinelli M and 9 co-authors. Institution: Care Policy and Evaluation Centre, London School of Economics and Political Science, London, UK. m.tinelli@lse.ac.uk. Major MEDLINE topics: Anticonvulsants, Epilepsy, Cost-Benefit Analysis, Autistic Disorder. Cited 2 times so far (Crossref); 42 references. The full text is freely available (open access, CC BY 4.0). Funded by: Commission européenne Office Européen de Lutte Antifraude.
Topics: Kinderkrankenpflege
Abstract (original language)
We examine the cost-effectiveness of treating epilepsy with anti-epileptic medicines in autistic children, looking at impacts on healthcare providers (in England, Ireland, Italy and Spain) and children’s families (in Ireland). We find carbamazepine to be the most cost-effective drug to try first in children with newly diagnosed focal seizures. For England and Spain, oxcarbazepine is the most cost-effective treatment when taken as additional treatment for those children whose response to monotherapy is suboptimal. In Ireland and Italy, gabapentin is the most cost-effective option. Our additional scenario analysis presents the aggregate cost to families with autistic children who are being treated for epilepsy: this cost is considerably higher than healthcare provider expenditure.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Care Policy and Evaluation Centre, London School of Economics and Political Science, London, UK. m.tinelli@lse.ac.uk.
- Care Policy and Evaluation Centre, London School of Economics and Political Science, London, UK.
- Atlantic Technological University, Sligo, Ireland.
- Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, School of Medicine, Hospital General Universitario Gregorio Marañón, Universidad Complutense, CIBERSAM, IiSGM, Madrid, Spain.
- Autistica, London, UK.
- Kings College London, London, UK.
Funding
- Commission européenne Office Européen de Lutte Antifraude
Cite
APA
Tinelli M, M., Roddy, A., Knapp, M., Arango, C., Mendez, M. A., Cusack, J., Murphy, D., Canitano, R., Oakley, B., & Quoidbach, V. (2024). Economic Evaluation of anti-epileptic Medicines for Autistic Children with Epilepsy. Journal of Autism and Developmental Disorders. https://doi.org/10.1007/s10803-023-05941-8
Vancouver
Tinelli M M, Roddy A, Knapp M, Arango C, Mendez MA, Cusack J, et al. Economic Evaluation of anti-epileptic Medicines for Autistic Children with Epilepsy. Journal of Autism and Developmental Disorders. 2024. doi:10.1007/s10803-023-05941-8
BibTeX
@article{TinelliM2024,
author = {Tinelli M, Michela and Roddy, Aine and Knapp, Martin and Arango, Celso and Mendez, Maria Andreina and Cusack, James and Murphy, Declan and Canitano, Roberto and Oakley, Bethany and Quoidbach, Vinciane},
title = {Economic Evaluation of anti-epileptic Medicines for Autistic Children with Epilepsy},
journal = {Journal of Autism and Developmental Disorders},
year = {2024},
doi = {10.1007/s10803-023-05941-8}
}
EUVIMED